Fig. 4From: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trialDifferences in medication tolerability according to the FIBSER Burden of side effects subscore. The percentage of patients with scores ≤2 in the tolerability subpopulation are shown at 6 weeks (visit 2) and 12 weeks (visit 3) for the study and control groups. *p < 0.05Back to article page